IMUX Stock Overview
A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Immunic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.99 |
| 52 Week High | US$2.11 |
| 52 Week Low | US$0.83 |
| Beta | 1.73 |
| 1 Month Change | 9.61% |
| 3 Month Change | 3.85% |
| 1 Year Change | -21.38% |
| 3 Year Change | -83.69% |
| 5 Year Change | -89.68% |
| Change since IPO | -95.91% |
Recent News & Updates
Recent updates
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
Apr 28We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate
Oct 25
Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation
Jan 22Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely
Oct 13Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?
Jun 27Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo
Oct 20Immunic stock gains on $60M oversubscribed PIPE financing
Oct 10Immunic GAAP EPS of -$0.72 in-line
Aug 04Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely
Jul 27Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?
Apr 13Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?
Dec 24Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation
Aug 13We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely
May 10Shareholder Returns
| IMUX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.9% | -2.6% | 3.9% |
| 1Y | -21.4% | -12.1% | 11.6% |
Return vs Industry: IMUX underperformed the US Biotechs industry which returned -15.3% over the past year.
Return vs Market: IMUX underperformed the US Market which returned 8% over the past year.
Price Volatility
| IMUX volatility | |
|---|---|
| IMUX Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: IMUX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IMUX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 91 | Daniel Vitt | imux.com |
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
Immunic, Inc. Fundamentals Summary
| IMUX fundamental statistics | |
|---|---|
| Market cap | US$96.78m |
| Earnings (TTM) | -US$100.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs IMUX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMUX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$100.51m |
| Earnings | -US$100.51m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMUX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 05:47 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunic, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Farmer | BMO Capital Markets Equity Research |
| William Wood | B. Riley Securities, Inc. |
| Tyler Bussian | Brookline Capital Markets |